AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 (AstraZeneca)
Two different dosing regimens demonstrated efficacy with one showing a better profile
No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222
